Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

CSV Delay in LIMS Implementation Caused by Template Non-Compliance in ALM Workflow

When Zamann Pharma Support was engaged to support the implementation of LabWare LIMS 8.0 at a Japanese pharmaceutical manufacturer, the objective was clearly defined from the beginning.

The project focused on three core deliverables: defining test plans for system validation, guiding key users to document test cases in the official Excel template, and uploading these test plans into ALM for approval and execution within the CSV lifecycle.

However, as the project progressed, a critical bottleneck emerged. Although the technology and validation framework were in place, the process itself was delayed due to human resistance. Despite structured training, clear instructions, and defined procedures, key users repeatedly modified the testing templates—changing formatting, deleting validation formulas, adding columns, and breaking auto-numbering rules. As a result, spreadsheets became incompatible with ALM uploads.

Consequently, this led to repeated rework, delayed test execution, and blocked approvals. Ultimately, this case demonstrated that CSV delays are not always driven by system complexity, but often by behavioral resistance to procedural control.

Challenges Faced

A detailed GAP analysis in Quality Management Systems is essential for identifying process deficiencies effectively.
  • Regulatory Scrutiny: Strict FDA inspections meant that even minor validation gaps could result in findings or penalties. Compliance required alignment with FDA 21 CFR Part 11, EMA Annex 11, and GAMP5, ensuring full traceability and data integrity.
  • Document Volume: Validation work involved extensive documentation, including plans, protocols, reports, traceability matrices, and change controls, significantly increasing complexity.
  • Regulatory Complexity: GAMP and FDA requirements demanded strong expertise in risk-based validation and lifecycle management, making compliance alignment challenging.
  • Time Sensitivity: GAP assessment and validation activities had strict deadlines, leaving little room for delays or rework.

Zamann Pharma Support’s Approach

  • Project Initialization: First, a structured kick-off meeting was conducted with all relevant stakeholders. This ensured alignment on goals, timelines, and key concerns. In addition, the validation lifecycle scope was mapped to define assessment boundaries.
  • Document Review: Next, all validation documents were systematically evaluated against FDA and GAMP requirements. This included URS, FS, VMP, IQ/OQ/PQ test protocols, traceability matrices, and change control records.
  • Key Compliance Evaluation: Furthermore, risk assessments were analyzed in line with GAMP risk-based validation principles. Testing protocols were reviewed for data integrity compliance, including audit trails and electronic signatures under 21 CFR Part 11. In parallel, change management and deviation handling processes were assessed for completeness and consistency.
  • Structured Findings Classification & CAPA Proposal Development: Findings were grouped into Critical, Major, and Minor GAPs based on regulatory impact. CAPA focused on revising URS/FS and strengthening test protocols for audit trail and e-signature compliance. Traceability, training, and templates were then updated to improve consistency and audit readiness.
  • CAPA Proposal Development:

    CAPA actions focused on closing validation gaps by revising URS and FS based on risk assessments, strengthening test protocols for audit trail and e-signature compliance, and improving traceability matrices. In addition, validation training and document templates were updated to enhance audit readiness and consistency.

Results Achieved

  • Regulatory Compliance Achieved: As a result of the GAP Assessment and CAPA implementation, the validation documentation was aligned with FDA and GAMP5 requirements. Therefore, overall compliance readiness improved significantly.
  • Improved Documentation Quality: In addition, documentation became more structured, standardized, and easier to manage during audits and inspections.
  • Risk Mitigation: By identifying and addressing critical gaps early, the client significantly reduced the risk of regulatory findings and inspection penalties.
  • Team Capability Enhancement: Moreover, through workshops and active involvement in CAPA planning, the internal team developed stronger understanding of validation principles and compliance expectations.
  • On-Time Delivery: Finally, despite initial delays, the assessment and remediation plan were completed within the required timeline, ensuring regulatory deadlines were met.
Laboratory
GMP qualification and lifecycle validation activities including IQ, OQ, and PQ supporting inspection readiness in pharmaceutical manufacturing.
Services

Qualification and Validation for GMP Systems

Our team supports the planning, execution, and maintenance of qualification and validation activities, including IQ, OQ, and PQ, to keep GMP-regulated systems compliant and under control.

Read More

Contact Us

Need help? Don't hesitate to get in touch
Zamann pharma support is committed to protecting and respecting your privacy, and we’ll use your personal information to administer your account and to provide the products and services you requested from us.

FAQ

1. Why do CSV timelines get delayed even when the LIMS system is fully validated?

CSV timelines usually fail because users modify controlled templates instead of following validated formats. As a result, ALM uploads break, traceability is lost, and validation execution gets delayed even when the system itself is compliant.

 

2. How does template modification impact audit readiness in validation workflows?

When users change validated Excel templates, they often break structure, formulas, and numbering logic. Therefore, audit trails become inconsistent, and inspectors may question data integrity and lifecycle control during inspections.

 

3. What is the most effective way to prevent human-driven validation delays in ALM-based CSV processes?

The most effective approach is strict template control combined with enforcement mechanisms. In addition, organizations should lock approved formats, monitor deviations, and link any unauthorized changes directly to CAPA and retraining workflows.